Jakubowska K, Naumnik W, Niklińska W, Chyczewska E
Department of Lung Diseases, Medical University of Bialystok, 14 Zurawia St., 15-540, Bialystok, Poland.
Adv Exp Med Biol. 2015;852:49-58. doi: 10.1007/5584_2015_115.
Lung cancer is associated with poor prognosis. The aim of this study was to evaluate the clinical usefulness of HMGB-1 (high-mobility group protein B1) and TGF-β (transforming growth factor beta) in patients with advanced non-small cell lung cancer (NSCLC). We studied 45 patients with NSCLC prior to chemotherapy, 23 patients with Besnier-Boeck-Schaumann (BBS) disease (sarcoidosis), and 15 healthy volunteers. HMGB-1 and TGF-β levels were measured in serum and BALF samples using ELISA method. A higher serum HMGB-1 and TGF-β levels were in NSCLC patients compared with the other groups. TGF-β concentration in BALF was significantly higher in NSCLC than in healthy controls (p=0.047) but lower than in BBS (p=0.016). Serum HMGB-1 in NSCLC correlated with age and gender while its level in BALF was associated with distant metastasis. A higher levels of HMGB-1 in the serum of NSCLC patients with progressive disease was linked with shorter overall survival and disease-free survival. We found a positive correlation between HMGB-1 and TGF-β in BALF of IIIB NSCLC group and overall survival (p=0.04; p=0.003). Our findings confirmed that the measurement of HMGB-1 and TGF-β levels in serum and BALF of patients with NSCLC prior to treatment may have clinical usefulness and predict poor prognosis.
肺癌与预后不良相关。本研究的目的是评估HMGB-1（高迁移率族蛋白B1）和TGF-β（转化生长因子β）在晚期非小细胞肺癌（NSCLC）患者中的临床应用价值。我们研究了45例化疗前的NSCLC患者、23例贝氏肉样瘤病（结节病）患者和15名健康志愿者。采用ELISA法检测血清和支气管肺泡灌洗液（BALF）样本中的HMGB-1和TGF-β水平。与其他组相比，NSCLC患者血清中的HMGB-1和TGF-β水平更高。NSCLC患者BALF中的TGF-β浓度显著高于健康对照组（p=0.047），但低于贝氏肉样瘤病患者（p=0.016）。NSCLC患者血清中的HMGB-1与年龄和性别相关，而其在BALF中的水平与远处转移相关。疾病进展的NSCLC患者血清中较高水平的HMGB-1与较短的总生存期和无病生存期相关。我们发现IIIB期NSCLC组BALF中的HMGB-1与TGF-β之间存在正相关，且与总生存期相关（p=0.04；p=0.003）。我们的研究结果证实，在治疗前检测NSCLC患者血清和BALF中的HMGB-1和TGF-β水平可能具有临床应用价值，并可预测预后不良。
